International Stem Cell Corp Faces Substantial Doubt on Going Concern, Reports Doubled Net Loss for 2025
Summary
International Stem Cell Corp's 2025 annual report reveals a going concern warning from both management and auditors, alongside a doubling of net losses and declining cash, signaling critical financial challenges.
Key Events
-
Substantial Doubt on Going Concern
Both management and the independent registered public accounting firm (BDO USA, P.C.) have expressed substantial doubt about the company's ability to continue as a going concern due to accumulated deficits, historical net losses, and insufficient cash to sustain operations for at least one year without additional financing.
-
Net Loss Doubled in 2025
The company reported a net loss of $418 thousand for the year ended December 31, 2025, a 100% increase from the $209 thousand net loss in 2024.
-
Flat Revenue and Declining Cash
Product sales remained flat at $9.1 million in 2025 compared to 2024, while cash on hand decreased from $1.23 million in 2024 to $993 thousand in 2025. Net cash provided by operating activities was a minimal $8 thousand in 2025.
-
Significant Potential Dilution
The company has 120 million shares of common stock authorized, with 8,004,389 shares outstanding. An additional 37,351,154 shares are reserved for future issuance (including options and convertible preferred stock), representing a potential dilution of approximately 466% if all reserved shares were issued.
Analysis
International Stem Cell Corporation's 2025 annual report highlights severe financial distress, with both management and auditors expressing substantial doubt about the company's ability to continue as a going concern. The net loss doubled year-over-year, and cash reserves declined, indicating an unsustainable operational trajectory without significant new financing. The company's heavy reliance on related-party debt and the substantial potential for future dilution further underscore its precarious financial position. Investors should be aware of the significant risks to the company's long-term viability.
At the time of this filing, ISCO was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.05 to $0.27. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.